Bottom Line: Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) as patients naïve to these treatments….
Read More
Promising immunotherapy uses cancer-killing cells to destroy malignant tumors
Researchers at McMaster University have developed a promising new cancer immunotherapy that uses cancer-killing cells genetically engineered outside the body to find and destroy malignant tumors. The modified "natural killer" cells can differentiate between cancer cells and healthy cells that…
Read More
Follow-Up Supports MammaPrint to Guide Chemo Decisions, Points to an ‘Age Effect’
NEW YORK (Reuters Health) – Longer-term follow-up data from the MINDACT trial confirm the clinical utility of the 70-gene MammaPrint assay to help guide chemotherapy decisions in women with early breast cancer, but also suggests that age may be a…
Read More
Phase 3 DREAM3R trial opens for malignant pleural mesothelioma
The DREAM3R phase three clinical trial is now enrolling patients with newly diagnosed unresectable malignant pleural mesothelioma (MPM) throughout the US, Australia, and New Zealand. The DREAM3R study builds on signals of effectiveness found in independent single-arm phase two trials,…
Read More
Liquid Biopsy After Hepatectomy Promising Aid in Metastatic Colorectal Cancer
NEW YORK (Reuters Health) – Liquid biopsy following resection of colorectal liver metastases allows non-invasive molecular profiling which may help spot hard-to-detect remaining disease, according to Houston-based researchers. Dr. Yun Shin Chun told Reuters Health by email that analysis of…
Read More
Detecting hidden circulating tumor cells in non-small cell lung cancer patients
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected…
Read More
Studies reveal the promise of newly engineered bispecific antibodies against tumor cells
Three studies – one each in Science, Science Translational Medicine, and Science Immunology – reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases….
Read More
Xenograft model for invasive lobular carcinoma simulates tumor with high accuracy
Invasive lobular carcinoma (ILC) is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It covers 10-15% of all breast cancer cases, has a high risk of late recurrence, unique metastatic sites, high sensitivity…
Read More
Technion team discovers new process for attacking cancer cells
When treating cancer, researchers are always searching for ways to remove cancer cells while minimizing damage to the rest of the body. One possible approach is to find processes unique to cancer cells, and which would allow specific targeting. If…
Read More
Sample Preparation for Fluorescence Microscopy
By Shelley Farrar, MSc, BSc Fluorescence Microscopy allows specimens to be studied with high sensitivity and specificity through the use of light. It works on the principle that energy emitted by certain types of materials can be detected as light,…
Read More